Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYP1B1 siRNA
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
CYP1B1 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the Cytochrome P450 1B1 (CYP1B1) enzyme. CYP1B1 is a member of the cytochrome P450 superfamily and is frequently overexpressed in various malignancies, including renal cell carcinoma (RCC). In these contexts, CYP1B1 promotes tumorigenesis by upregulating CDC20 and downregulating the pro-apoptotic protein DAPK1. By utilizing the RNA interference (RNAi) pathway, CYP1B1 siRNA facilitates the degradation of CYP1B1 mRNA, leading to reduced protein levels. Preclinical studies have demonstrated that this silencing results in decreased cell proliferation, migration, and invasion, while simultaneously inducing apoptosis in RCC cell lines, suggesting its potential as a therapeutic strategy for cancer treatment.
- Other names
- siRNA targeting CYP1B1CYP1B1-silencing siRNACYP-1B1-silencing siRNACYP 1B1-silencing siRNA
02
Targets
CYP1B1 (Cytochrome P450 1B1)
Beyond the preview
Go deeper on CYP1B1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYP1B1 siRNA.